U.S. License Holder:
Novo Nordisk Inc.
Date of License:
June-07-2000
Last Update:
January-23-2021
FDA-Approved Indications
NOVOLOG (insulin aspart recombinant) is a rapid acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.
Approved Foreign Follow-On Biologics / Biosimilars
Biosimilars Approved In The E.U.
Insulin Aspart Sanofi (Sanofi) (July-2020)